TABLE 2

Effects of GCKR rs1260326 on TG levels and glucose homeostasis parameters using up to four repeated measurements over the 9-year follow-up study

Number of observationsPΔ% (95% CI)Overall mean ± SD
CCCTTT
Fasting plasma glucose (mmol/l)
    additive13,9418 × 10−13−1.43 (−1.81 to −1.04)5.41 ± 0.705.34 ± 0.695.27 ± 0.64
    dominant2 × 10−10−1.92 (−2.50 to −1.33)
    recessive2 × 10−7−1.85 (−2.54 to −1.17)
Fasting serum insulin (pmol/l)
    additive13,9153 × 10−7−4.23 (−5.80 to −2.63)52.9 ± 37.4851.5 ± 36.6647.9 ± 31.57
    dominant3 × 10−5−5.19 (−7.54 to −2.77)
    recessive3 × 10−5−6.13 (−8.86 to −3.32)
HOMA-IR
    additive12,0421 × 10−8−5.69 (−7.57 to −3.79)2.15 ± 1.752.06 ± 1.701.90 ± 1.53
    dominant1 × 10−6−7.20 (−9.98 to −4.34)
    recessive7 × 10−6−7.87 (−11.10 to −4.52)
HOMA-B
    additive12,0311−0.04 (−1.99 to 1.95)101.3 ± 69.15103.1 ± 80.51101.4 ± 77.25
    dominant0.70.57 (−2.39 to 3.61)
    recessive0.6−0.90 (−4.30 to 2.63)
Fasting plasma TG (mmol/l)
    additive13,9551 × 10−43.41 (1.68 to 5.16)1.12 ± 0.871.19 ± 0.971.21 ± 0.73
    dominant1 × 10−34.24 (1.61 to 6.94)
    recessive1 × 10−35.00 (1.90 to 8.19)
  • The P values indicated are nominal P values. Δ%, percentage of variation of the trait per supplementary minor T-allele. P values and Δ% are from mixed models adjusted for age, sex, and BMI. HOMA-B, homeostasis model assessment of β-cell function; HOMA-IR, homeostasis model assessment of insulin resistance; TG, triglycerides.